The drug treats fast-growing, deadly brain cancers with no effective treatment.
Typically, a promising new experimental drug arrives on the scene with a flourish. But sometimes, it’s a long and winding road.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Agreement will expand clinical trials of glioblastoma drug